Combretastatin A1 phosphate (Synonyms: Oxi4503; CA1P; Combretastatin A1 diphosphate)

Name: Combretastatin A1 phosphate
Brand: MedChemExpress
SKU: HY-16147
Rating: 4.5 (1 reviews)

Cat. No.: HY-16147 Purity: 98.00%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Combretastatin A1 phosphate (Oxi4503; CA1P; Combretastatin A1 diphosphate) is a potent vascular disruptive agent. Combretastatin A1 phosphate exerts anti-angiogenic effects on tumors. Combretastatin A1 phosphate has the potential for the research of pancreatic neuroendocrine tumors.

For research use only. We do not sell to patients.

Combretastatin A1 phosphate Chemical Structure

CAS No. : 288847-35-8

Size	Price	Stock	Quantity
1 mg	USD 276	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 690	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 1105	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 2320	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 3700	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 5920	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Combretastatin A1 phosphate:

Combretastatin A-1 phosphate tetrasodium Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vivo

Combretastatin A1 phosphate (100 mg/kg; I.p.; once at day 16 post tumor induction) shows anti-tumor activity and exerts anti-angiogenic effects on tumors in mice when combined with Sunitinib (HY-10255A)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male CBA mice (CRC liver metastasis)^[2]
Dosage:	100 mg/kg (received 40 mg/kg of Sunitinib daily from day 14 to 21 post tumor induction)
Administration:	I.p.; once at day 16 post tumor induction
Result:	Demonstrated a significantly decreased mean liver weight compared to livers from non tumor bearing animals, significantly reduced tumor vessels.

Clinical Trial

Molecular Weight

492.31

Formula

C₁₈H₂₂O₁₂P₂

CAS No.

288847-35-8

Appearance

Solid

Color

Off-white to pink

SMILES

COC1=C(OP(O)(O)=O)C(OP(O)(O)=O)=C(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (203.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0312 mL	10.1562 mL	20.3124 mL
5 mM	0.4062 mL	2.0312 mL	4.0625 mL
10 mM	0.2031 mL	1.0156 mL	2.0312 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (10.16 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (10.16 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.00%

Select Batch:

Data Sheet (279 KB) SDS (252 KB)

COA (257 KB) HNMR (236 KB) LCMS (98 KB)

Handling Instructions (2659 KB)

References

[1]. Patterson DM, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012 Mar 1;18(5):1415-25. [Content Brief]

[2]. Nguyen L, et al. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis. BMC Cancer. 2016 Jul 26;16:533. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.0312 mL	10.1562 mL	20.3124 mL	50.7810 mL
	5 mM	0.4062 mL	2.0312 mL	4.0625 mL	10.1562 mL
	10 mM	0.2031 mL	1.0156 mL	2.0312 mL	5.0781 mL
	15 mM	0.1354 mL	0.6771 mL	1.3542 mL	3.3854 mL
	20 mM	0.1016 mL	0.5078 mL	1.0156 mL	2.5391 mL
	25 mM	0.0812 mL	0.4062 mL	0.8125 mL	2.0312 mL
	30 mM	0.0677 mL	0.3385 mL	0.6771 mL	1.6927 mL
	40 mM	0.0508 mL	0.2539 mL	0.5078 mL	1.2695 mL
	50 mM	0.0406 mL	0.2031 mL	0.4062 mL	1.0156 mL
	60 mM	0.0339 mL	0.1693 mL	0.3385 mL	0.8464 mL
	80 mM	0.0254 mL	0.1270 mL	0.2539 mL	0.6348 mL
	100 mM	0.0203 mL	0.1016 mL	0.2031 mL	0.5078 mL

Combretastatin A1 phosphate Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Combretastatin A1288847-35-8Oxi4503 CA1P Combretastatin A1 diphosphateCombretastatin A 1Combretastatin A-1Oxi 4503Oxi-4503Othersanti-angiogenicanti-cancerSunitinibpancreatic neuroendocrineliver metastasisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Combretastatin A1 phosphate (Synonyms: Oxi4503; CA1P; Combretastatin A1 diphosphate)

Customer Review

Other Forms of Combretastatin A1 phosphate:

Combretastatin A1 phosphate Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Combretastatin A1 phosphate Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report